Loading
A phase 3 trial of Sacituzumab govitecan, Topotecan, Amrubicin in small-cell lung cancer, run by Gilead Sciences, now recruiting.
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06801834 by Gilead Sciences, with 695 participants planned, started 2025-04-04 and due to reach its primary completion in 2029-10. Interventions recorded: Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available). Conditions listed: Extensive Stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Amrubicin, Lurbinectedin, Topotecan, Extensive-stage small-cell lung cancer.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Lurbinectedin, Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/